Cel-Sci Corporation (NYSE: CVM) has captured the attention of investors with its eye-popping potential upside of 9,657%, according to analyst target price ranges. This biotechnology firm, headquartered in Vienna, Virginia,..
Cross Country Healthcare, Inc. (NASDAQ: CCRN) stands as a pivotal player in the healthcare staffing industry, offering a breadth of talent management services across the United States. Despite its robust..
MeiraGTx Holdings plc (NASDAQ: MGTX), a dynamic player in the biotechnology sector, is making waves with its focus on genetic medicine innovations, despite the inherent challenges in the biotech industry...
Organogenesis Holdings Inc. (NASDAQ: ORGO) stands at a pivotal crossroads, intriguing investors with its potential for significant upside, despite some challenging performance metrics. With its market capitalization at $376.76 million,..
For investors eyeing opportunities in the healthcare sector, Standard BioTools Inc. (NASDAQ: LAB) presents a compelling narrative characterized by innovative technology and significant potential upside. At its current price of..
Maze Therapeutics, Inc. (NASDAQ: MAZE) is catching the eye of investors with its promising pipeline and substantial growth potential within the biotechnology sector. Based in South San Francisco, California, Maze..
Fortrea Holdings Inc. (FTRE), a recently established player in the healthcare sector, is capturing attention for its potential upside of nearly 60%, a figure that could pique the interest of..
For investors with an eye on the healthcare sector, Kamada Ltd. (NASDAQ: KMDA) presents a compelling opportunity. Headquartered in Rehovot, Israel, this specialty and generic drug manufacturer is making waves..
For investors with a keen eye on the biotechnology sector, Celcuity Inc. (NASDAQ: CELC) presents an intriguing opportunity. This clinical-stage biotech company, headquartered in Minneapolis, Minnesota, is carving a niche..
Autolus Therapeutics plc (NASDAQ: AUTL) is capturing investor attention with its significant potential upside of over 551%, according to analyst ratings. As a clinical-stage biopharmaceutical company, Autolus is at the..
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, has captured the attention of investors with a remarkable potential upside of 287.89%. Specializing in transformative cell and exosome-based therapeutics, Capricor..
Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning player in the biotechnology sector, is capturing investor attention with its promising pipeline and significant upside potential. Despite its relatively modest market capitalization..
LifeMD, Inc. (NASDAQ: LFMD) is making significant strides in the healthcare sector, particularly within the burgeoning field of telehealth. With a market capitalization of $522.65 million, this healthcare company is..
Theravance Biopharma, Inc. (NASDAQ: TBPH), a dynamic player in the biotechnology sector, is drawing attention with its substantial growth potential, evidenced by an impressive potential upside of 60.70% according to..
Personalis, Inc. (NASDAQ: PSNL) is carving a niche in the rapidly evolving healthcare sector, specifically within the diagnostics and research industry. With its focus on advanced cancer genomic tests and..
Opthea Limited (NASDAQ: OPT), a biopharmaceutical company headquartered in South Yarra, Australia, has garnered attention in the biotechnology sector for its innovative approach to treating eye diseases. Specializing in the..
Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector. With a focus on developing novel therapeutics for conditions linked to dysfunctional signaling of..
For investors with a keen eye on the biotechnology sector, MBX Biosciences, Inc. (NASDAQ: MBX) presents itself as a compelling opportunity. Based in Carmel, Indiana, MBX is a clinical-stage biopharmaceutical..
Kura Oncology, Inc. (NASDAQ: KURA) is turning heads in the biotechnology sector with its ambitious portfolio of cancer treatment candidates and a staggering 318% potential upside. As a clinical-stage biopharmaceutical..
Zenas BioPharma, Inc. (ZBIO) is capturing investor attention with a potential upside of 180.72%, according to recent analyst ratings. As a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, Zenas is..
